news and event

8.15.2016 5th US patent (#9 ,381,680 ) was issued.

2.15.2013 TheraJect published the co-research results in PNAS with King's
College.

8.6.2012 TheraJect was granted Phase II research fund from NSF for
Sumatriptan Delivery Research Program till 2014.

12.23.2011 The Research Article was published in Journal of Pharmaceutical
Sciences. Dissolvable Microneedle Patches for the Delivery of Cell-Culture-
Derived Influenza Vaccine Antigens.

11.22.2011 4th US patent (#8,062,573) was issued

7.1.2011 TheraJect was granted research fund from NSF for Sumatriptan
Delivery Research Program.

7.10.2007 TheraJect presented two posters (1st and 2nd) at the 34th CRS
Annual Meeting in Long Beach, California.

6.5.2007 TheraJect Chief Technical Officer Dr. Sung-Yun Kwon presented
TheraJect Interdermal Patch for Influenza at WHO Conference

5.1.2007 3 rd US patent (#7 ,2 11 ,0 62 ) was issued.

2.27.2007 2 nd US patent (#7 ,1 82 ,7 47 ) was issued.

10.30.2006 TheraJect p resented 1st pre-clinical data of Influenza vaccine
delivery in 2006 AAPS Annual Meeting in San Antonio, Texas.

7.24.2006 TheraJect presented at the 3 3 r d CRS Annual Meeting in V ienn a ,
A ustria .

7.19.2006 TheraJect is part of the Patterson HIV Vaccine Development
Consortium, which is funded by a grant from the Bill & Melinda Gates
Foundation.

7.15.2006 TheraJect was granted research fund from NIH/NIA for PTH
Delivery Research Program.

9.20.2005 1 st US patent (#6,945,952) is issued.

6.20.2005 TheraJect presented at the 32nd CRS Annual Meeting in Miami,
Florida.

6.5.2005 TheraJect presented at the 2005 AAPS National Biotechnology in
San Francisco, California.

10.26.2004 TheraJect was granted research fund from NIAID for Biodefense
Research Program.

6.15.2004 TheraJect presented at the 31st CRS Annual Meeting in Honolulu,
Hawaii.